Evidence map›Paper›PMID 34211843›Full record

ArticleFrontiers in oncology2021

Expression Profiling of Glioblastoma Cell Lines Reveals Novel Extracellular Matrix-Receptor Genes Correlated With the Responsiveness of Glioma Patients to Ionizing Radiation.

Rodolfo Bortolozo Serafim, Patrick da Silva, Cibele Cardoso, Luis Fernando Macedo Di Cristofaro, Renato Petitto Netto, Rodrigo de Almeida, Geovana Navegante, Camila Baldin Storti, Juliana Ferreira de Sousa, Felipe Canto de Souza and 5 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach.International journal of environmental research and public health · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rodolfo Bortolozo SerafimSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Patrick da SilvaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Cibele CardosoCenter for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
Luis Fernando Macedo Di CristofaroSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Renato Petitto NettoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Rodrigo de AlmeidaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Geovana NaveganteSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Camila Baldin StortiCenter for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
Juliana Ferreira de SousaRadiation Oncology Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.
Felipe Canto de SouzaCenter for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
Rodrigo PanepucciCenter for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
Cristiano Gallina MoreiraSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Larissa Siqueira PennaSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.
Wilson Araujo SilvaCenter for Cell-Based Therapy (CTC), Regional Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
Valeria ValenteSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most lethal and frequent type of brain tumor, leading patients to death in approximately 14 months after diagnosis. GBM treatment consists in surgical removal followed by radio and chemotherapy. However, tumors commonly relapse and the treatment promotes only a slight increase in patient survival. Thus, uncovering the cellular mechanisms involved in GBM resistance is of utmost interest, and the use of cell lines has been shown to be an extremely important tool. In this work, the exploration of RNAseq data from different GBM cell lines revealed different expression signatures, distinctly correlated with the behavior of GBM cell lines regarding proliferation indexes and radio-resistance. U87MG and U138MG cells, which presented expressively reduced proliferation and increased radio-resistance, showed a particular expression signature encompassing enrichment in many extracellular matrix (ECM) and receptor genes. Contrasting, U251MG and T98G cells, that presented higher proliferation and sensibility to radiation, exhibited distinct signatures revealing consistent enrichments for DNA repair processes and although several genes from the ECM-receptor pathway showed up-regulation, enrichments for this pathway were not detected. The ECM-receptor is a master regulatory pathway that is known to impact several cellular processes including: survival, proliferation, migration, invasion, and DNA damage signaling and repair, corroborating the associations we found. Furthermore, searches to The Cancer Genome Atlas (TCGA) repository revealed prognostic correlations with glioma patients for the majority of genes highlighted in the signatures and led to the identification of 31 ECM-receptor genes individually correlated with radiation responsiveness. Interestingly, we observed an association between the number of upregulated genes and survivability greater than 5 years after diagnosis, where almost all the patients that presented 21 or more upregulated genes were deceased before 5 years. Altogether our findings suggest the clinical relevance of ECM-receptor genes signature found here for radiotherapy decision and as biomarkers of glioma prognosis.

Indexed as

ECM-receptorsexpression profilingextracellular matrixGBM cell linesglioblastomaradioresistance

Identifiers

PMID34211843
PMCPMC8240593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.